Marker Therapeutics, Inc. is a Houston-based biotechnology company focused on the development and commercialization of innovative T cell-based immunotherapies for patients with various blood and solid tumor cancers. Their groundbreaking MultiTAA technology utilizes non-genetically engineered T cells that can recognize and eliminate multiple tumor targets, aiming to create more precise and safer treatments with broad and long-lasting anti-cancer effects.
With a commitment to advancing the field of immunotherapy, Marker Therapeutics aims to provide patients with next-generation therapies that offer improved outcomes and quality of life. Through their cutting-edge research and development efforts, they strive to revolutionize cancer treatment and make a significant impact in the fight against cancer.
Generated from the website